The TRIUMPH trials and long-term cardiovascular outlook Understanding the long-term cardiovascular safety of retatrutide requires looking at the broader clinical trial program being conducted by Eli Lilly
On Wednesday, the Food and Drug Administration issued a warning, calling compounded GLP-1 medications "risky for patients." "FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 (glucagon-like peptide-1 (GLP-1) receptor agonists) drugs, including semaglutide and tirzepatide, as an option for weight loss," the FDA said
These include severe pain, extensive bruising, signs of infection such as increasing warmth, spreading redness, pus formation, or fever
At follow-up after 28 months of treatment, the patient presented a dorsal curve (10) similar to the original congenital curvature
These alterations can modulate immune mechanisms, including T-cell polarization and autoantibody generation, thereby playing a role in the pathogenesis of HT (Lee et al
Our results delineate that TMPRSS2-PAR2 signaling regulates postprandial GIP release in lean mice, but that this signaling axis is overlaid by additional functions of TMPRSS2 in the context of hypercaloric weight gain and the associated dysregulation of glucose homeostasis and insulin resistance
